A conditional marketing authorization has been recommended for Translarna (ataluren) , an orphan-designated medicine, by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), for the treatment for Duchenne muscular dystrophy caused by nonsense mutations. An orphan drug is a pharma agent developed specifically to treat a rare medical condition that is also known as orphan disease. Translarna is to be used in patients aged five years and older ...
Read MoreYou have just read an article categorized health
titled Ataluren Recommended for Treatment of Duchenne Muscular Dystrophy in Europe.
Written by:
editor - Tuesday, May 27, 2014
There are currently no comments for "Ataluren Recommended for Treatment of Duchenne Muscular Dystrophy in Europe"
Post a Comment